The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab

Richard Kelly, Louise Arnold, Stephen Richards, Anita Hill, Charlotte Bomken, John Hanley, Andrew Loughney, Jon Beauchamp, Gus Khursigara, Russell P. Rother, Elizabeth Chalmers, Andrew Fyfe, Edward Fitzsimons, Ryotaro Nakamura, Anna Gaya, Antonio M. Risitano, Jörg Schubert, Derek Norfolk, Nigel Simpson and Peter Hillmen

1Institute of Oncology, St James’s University Hospital, Leeds, 2Department of Haematology, Bradford Royal Infirmary, Bradford, 3Department of Haematology Royal Victoria Infirmary, 4Department of Obstetrics, Royal Victoria Infirmary, Newcastle-Upon-Tyne, 5Alexion Pharmaceuticals Inc, Guilford, UK, 6Alexion Pharmaceuticals Inc, Cheshire, CT, USA, 7Department of Haematology, Queen Mothers Hospital, Glasgow, 8Department of Haematology, Gartnavel General Hospital, Glasgow, UK, 9Division of Hematology & Bone Marrow Transplant, City of Hope National Medical Center & Beckman Research Institute, Duarte, CA, USA, 10Department of Hematology, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona, Spain, 11Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy, 12Saarland Univ. Med. School, Homburg/Saar, Germany, 13Leeds Teaching Hospitals NHS Trust and NHS Blood and Transplant, and 14Department of Obstetrics Leeds General Infirmary, Leeds, UK

Summary

In Paroxysmal nocturnal haemoglobinuria (PNH), pregnancy is associated with increased maternal and foetal complications to such an extent that the condition has been considered relatively contra-indicated in PNH. Eculizumab has revolutionized the treatment of PNH. We evaluate its use in pregnancy to date. We report on seven patients exposed to eculizumab at different stages of pregnancy including the first two patients to receive the drug from conception to delivery. There was no evidence of complement blockade from cord blood samples taken at delivery. Eculizumab appears safe to use in this setting and is likely to prevent many of the complications usually observed.

Keywords: Paroxysmal Nocturnal Haemoglobinuria (PNH), pregnancy, eculizumab.
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired disorder of haemopoietic stem cells resulting in the expansion of a haemopoietic clone of cells with a mutated PIGA gene (Takeda et al, 1993). This mutation disrupts glycosphingolipid synthetase (GPI) biosynthesis, leading to reduced or absent expression of GPI-linked cell surface proteins (Kinoshita et al, 1997). Affected individuals have intravascular haemolysis as their erythrocytes are more susceptible to attack from complement. Clinical manifestations of the disease include anaemia, dysphagia, erectile dysfunction, haemoglobinuria, pulmonary hypertension, renal impairment and thromboembolism. Thrombosis is the main cause of mortality in PNH, accounting for 40–67% of PNH-related deaths (Hillmen et al, 2007). There is an increased risk of venous and arterial thrombosis with pulmonary, lower limb, hepatic and cerebral veins being the commonest sites affected (Hillmen et al, 1995; de Latour et al, 2008).

Historically, the management of PNH patients during pregnancy has been challenging and pregnancy itself has generally been discouraged (Bais et al, 1994; Bjorge et al, 2003; Fieni et al, 2006). Intravascular haemolysis and anaemia are frequently more severe than in the non-pregnant state with increased transfusion requirements throughout pregnancy (Spencer, 1980; Ray et al, 2000; Tichelli et al, 2002). Thrombocytopenia is also more common and platelet counts typically fall to <50 × 10⁹/l (Ray et al, 2000). Maternal and foetal morbidity and mortality are increased in PNH both during the pregnancy and, for the mother, during the post-partum period (Ray et al, 2000; Tichelli et al, 2002; Fieni et al, 2006). Maternal mortality rates of 12–21% have been reported, with the main risks being thromboembolism and infection (Ray et al, 2000; Fieni et al, 2006). An increase in foetal mortality relates to premature births with only half of pregnancies progressing to term and mortality rates reported of 7–9% (Ray et al, 2000; Fieni et al, 2006).

Eculizumab is a humanized monoclonal antibody that binds to the complement protein C5, preventing its cleavage, and thereby blocking the formation of the terminal components of the complement cascade whilst keeping the proximal components intact (Thomas et al, 1996). It is given initially as a weekly intravenous infusion at a dose of 600 mg for 4 weeks, followed by 900 mg every 14 days (Hillmen et al, 2004, 2006; Brodsky et al, 2008). Clinical trials in PNH patients have shown that eculizumab reduces haemolysis and subsequently stabilizes haemoglobin levels, reduces transfusion requirements and improves quality of life (Hillmen et al, 2004, 2006; Brodsky et al, 2008). Eculizumab has dramatically altered the treatment of PNH. Young women on treatment feel symptomatically better, so the question of eculizumab use during pregnancy is increasingly likely. Here we present our experience in the use of eculizumab in pregnancy.

**Methods**

Information was collected on seven patients on eculizumab: five who became pregnant during the clinical trials and a further two patients who became pregnant after the clinical trials. Pregnancy was an exclusion criterion in the eculizumab clinical studies therefore only very limited data exists regarding its use during pregnancy. Three of these patients received eculizumab treatment either during the last trimester (starting eculizumab at week 27) or throughout gestation to term. Maternal blood, cord blood and breast milk samples were analysed to assess the distribution of eculizumab in these patients as IgG antibodies can cross the placental barrier. Patient characteristics are shown in Table I.

**Results**

There were five reported pregnancies from 106 female patients during the clinical trials of eculizumab in PNH (Hillmen et al, 2004, 2006; Brodsky et al, 2008). The trial protocols specified withdrawal of patients from the trial and cessation of eculizumab for patients who became pregnant during the study.

**Patients during eculizumab clinical trials**

Patient 1 elected to terminate her pregnancy and continued eculizumab.

Patients 2, 3 and 4 discontinued eculizumab treatment at 5, 14 and 4 weeks gestation, respectively. These patients delivered healthy newborn babies without any adverse effects from the eculizumab given during the early stages of their pregnancies. Patient 3 developed hyperpyrexia and hypertension shortly after delivery. She was diagnosed with pyrexia of unknown origin, treated and subsequently discharged. There were no other reported postpartum complications.

Patient 5 conceived having been on eculizumab for 5 years. She withdrew from the extension study and continued eculizumab off trial throughout her pregnancy. Prior to conceiving she needed occasional transfusions, around 3–4/l year. During her pregnancy her transfusion requirement increased to every 2–4 weeks. Her platelet count was normal before the pregnancy and remained within the normal range whilst she was pregnant. She had no prior history of thrombosis but is heterozygous for the F2 20201A mutation. Anticoagulation with low molecular weight heparin (LMWH) is routine practice during pregnancy in PNH and at week 8 of gestation, LMWH was commenced (Tichelli et al, 2002). During week 26 of her pregnancy she became unwell with haemoglobinuria 3 or 4 days prior to her eculizumab infusion. She again became unwell with breakthrough haemolysis 12 days after her last infusion. During this episode her lactate dehydrogenase (LDH) level became elevated and serum eculizumab level was subtherapeutic confirming breakthrough haemolysis. The interval between eculizumab infusions was reduced to 12 days for the remainder of the pregnancy without further evidence of...
Table I. Summary of patient characteristics.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Granulocyte clone size (%)</th>
<th>LDH At Baseline (i/u per l)</th>
<th>Eculizumab use in pregnancy</th>
<th>Last LDH During Pregnancy (i/u per l)</th>
<th>Maternal eculizumab levels (µg/ml)</th>
<th>Cord eculizumab levels (µg/ml)</th>
<th>Complications in pregnancy</th>
<th>Outcome</th>
<th>Anticoagulation Before pregnancy</th>
<th>Anticoagulation During pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>24</td>
<td>69-6</td>
<td>1336</td>
<td>Up to 5 weeks gestation</td>
<td>200*</td>
<td>NA</td>
<td>zNM</td>
<td>No</td>
<td>Elective termination</td>
<td>Not known</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>92-9</td>
<td>2376</td>
<td>Up to 5 weeks gestation</td>
<td>269*</td>
<td>NM</td>
<td>NM</td>
<td>No</td>
<td>Healthy baby</td>
<td>Warfarin</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>95-8</td>
<td>2014</td>
<td>Up to 14 weeks gestation</td>
<td>261*</td>
<td>NM</td>
<td>NM</td>
<td>Postpartum PUO</td>
<td>Healthy baby</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>87-5</td>
<td>1263</td>
<td>Up to 4 weeks gestation</td>
<td>272*</td>
<td>NM</td>
<td>NM</td>
<td>No</td>
<td>Healthy baby</td>
<td>Not known</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>99-7</td>
<td>10 300</td>
<td>All pregnancy &amp; postpartum</td>
<td>703</td>
<td>116-1</td>
<td>Undetected</td>
<td>Breakthrough haemolysis</td>
<td>Healthy term baby</td>
<td>No</td>
<td>Prophylactic LMWH</td>
</tr>
<tr>
<td>6</td>
<td>35</td>
<td>97-6</td>
<td>1616</td>
<td>From week 27 &amp; postpartum</td>
<td>387</td>
<td>80-5</td>
<td>Twin 1 19-2</td>
<td>Postpartum haemorrhage</td>
<td>Healthy twins at 35 weeks</td>
<td>No</td>
<td>Therapeutic LMWH</td>
</tr>
<tr>
<td>7</td>
<td>28</td>
<td>98-1</td>
<td>2642</td>
<td>All pregnancy &amp; postpartum</td>
<td>414</td>
<td>63-2</td>
<td>Undetected</td>
<td>Pre-eclampsia</td>
<td>Healthy baby at 28 weeks</td>
<td>Warfarin</td>
<td>Therapeutic LMWH</td>
</tr>
</tbody>
</table>

LDH, Lactate dehydrogenase; PUO, pyrexia of unknown origin; NM, not measured.

*These LDH values were taken at the beginning of the pregnancy before eculizumab treatment was stopped.
intravascular haemolysis. She had a normal vaginal delivery at term with a healthy 4 kg baby. Serum samples at delivery showed therapeutic levels of eculizumab in the mother with no eculizumab detected in the cord blood. Breast milk was analysed at days 1, 2, 3, 9 and 10 after delivery with no eculizumab detected.

Patients treated with eculizumab after the clinical trials

Patient 6 was diagnosed with PNH during in vitro fertilization and embryo storage for fallopian tube disease. She was treated with eculizumab for 2 years prior to stopping the drug for embryo implantation. She started therapeutic LMWH in the first trimester and recommenced eculizumab at week 27 of her twin pregnancy with the standard induction regime. She continued to have evidence of intravascular haemolysis with haemoglobinuria and a raised LDH, and so received eculizumab 900 mg weekly until an elective caesarean section was performed at 35 weeks gestation. Two healthy babies were born weighing 24 and 2 kg. She developed a post-partum haemorrhage whilst on warfarin, requiring treatment with prothrombin complex concentrate (PCC) and uterine artery embolization. Her condition was further complicated by a portal vein thrombosis thought to have been precipitated by the reversal of her anticoagulation with PCC. Serum samples at delivery showed therapeutic levels of eculizumab in the mother and low levels in the cords of both twins that were within the background levels for the assay and insufficient to block complement.

Patient 7 was diagnosed with PNH following treatment for aplastic anaemia 2 years previously at which time she developed hypertension. She conceived after being on eculizumab for 6 years and at week 5 gestation her warfarin was changed to LMWH. She remained well throughout her pregnancy until week 28 of gestation when she developed pre-eclampsia. She did not require transfusions during the pregnancy and her platelet count remained within the normal range before, during and after the pregnancy. A caesarean section was performed, delivering a 900 g baby. The baby was found to have meconium plug syndrome, which is a functional immaturity of the colon associated with prematurity. Serum samples at delivery showed therapeutic levels of eculizumab in the mother with no eculizumab detected in the cord blood. Both mother and baby remain well.

Conclusions

Based on our observations eculizumab may be safe to use in treating pregnant patients with PNH. However this conclusion is based solely on data from three patients treated and this report does not prove either the safety or efficacy of eculizumab in pregnancy. Many more patients need to be treated with eculizumab during pregnancy to determine its safety in this setting. Patient 7 did develop pre-eclampsia and her foetus had meconium plug syndrome despite eculizumab treatment. Eculizumab does not appear to cross the placenta or be excreted in breast milk but this needs to be confirmed in further patients. We report no long-term adverse effects in the children born who now vary from the youngest at 4 months old to the eldest at 16 months old. We observed no maternal morbidity that was attributable to PNH.

The dose of eculizumab required to block complement during the latter stages of pregnancy appeared to be greater than in the non-pregnant state, but again this needs to be confirmed in other pregnancies. Break-through from complement blockade manifests itself with patients experiencing haemoglobinuria prior to their next dose of eculizumab even in patients who had been well controlled on the standard dose for years prior to becoming pregnant.

All pregnant patients with PNH should be closely monitored during pregnancy by both haematology and obstetric specialists. In view of the risks associated with pregnancy in PNH the use of low molecular weight heparin should be considered as soon as pregnancy is confirmed. It appears that eculizumab can be safely used throughout pregnancy and theoretically it would be expected to reduce the complications of PNH frequently seen during pregnancy. This initial report of the use of eculizumab throughout pregnancy is encouraging, however more evidence on its use in this setting is needed.

Acknowledgement

We would like to thank Professor Bruno Rotoli for both his contribution to this work and to scientific research into PNH. Sadly Professor Rotoli died in 2009.

Disclosure of conflicts of interest

E.C. has received honoraria from Alexion Pharmaceuticals. R.K., A.H., S.R. and R.N. have received honoraria and have sat on advisory boards for Alexion Pharmaceuticals. J.S., A.R. and P.H. have received honoraria, research funding and have sat on advisory boards for Alexion Pharmaceuticals. J.B., G.K. and R.R. are employed by and have equity ownership in Alexion Pharmaceuticals.

References


